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1) Context:   
This study was conducted by the Belgian Poison Centre and the department of Public Health of Ghent University.  




Antidotes are important in the urgent treatment of certain poisonings. When used correctly and at the right time, 
they can reduce morbidity, mortality and the length of hospital stay. However, hospitals worldwide are confronted 
with a lack of availability of certain antidotes. It is unclear whether Belgian hospitals are facing the same problem 
and what role the Belgian Poison Centre could play in increasing the availability of antidotes, if necessary. 
 
4) Intervention 
The aim of this study was to investigate the availability of 22 antidotes in all Belgian hospitals with an emergency 
service and to optimize the stockpile of antidotes of the Belgian Poison Centre. A third objective was to investigate 
at hospital level the maintenance cost to hold a selection of antidotes. Furthermore, to explore the added value to 
develop an online platform by the BPC with shared information on the real-time availability of antidotes in Belgian 
hospitals. In the context of preparedness for chemical incidents, a last objective was to verify if hospitals met the 
government’s requirement to maintain a stock of atropine equal to twice their annual consumption.    
 
 
6) Strategy for change 
An online questionnaire was sent between February and April 2018 to all 126 hospitals with an emergency service. 
Selection of 22 included antidotes was based on the most frequent poisonings in Belgium, of which 12 antidotes 
were marked on account of evidence based proof of efficacy. For each hospital the list of available antidotes was 
compared with the 12 marked antidotes in order to calculate the expense of an optimal availability to treat a 75 kg 
patient for the first 24 hours.  
 
7) Measurement of improvement 
 
Response rate was 29%, of which 4 university hospitals and 33 non-university. Methylene blue, deferoxamin, 
hydroxocobalamin, calcium gluconate and intravenous lipid emulsion were available in more than 60% of the 
hospitals and 42% of hospitals held an atropine stock that met the imposed quantity. Digoxine immune fab (DIF) 
was ordered most frequently in urgent cases and was considered to be the most important antidote to be available 
via the depot of the Belgian Poison Centre. The availability of the 12 marked antidotes in the hospitals could be 
realized with an average extra budget of less than €1,000/year without DIF or €3,500/year with DIF (based on the 
cost of six vials of Digifab®). Most respondents were interested in an online platform sharing the stock of other 
hospitals in real time, developed and controlled by the BPC. 
 
6) Lessons learnt 
Not all antidotes commonly used in toxicology are available in the Belgian hospitals and most hospital pharmacies 
do not comply with the requirements for atropine storage. A minor investment will improve availability of the 
selected antidotes.  
 
7) Messages for others 
Mutual cooperation between hospitals and the BPC, together with the development of a real-time online platform 
by the BPC, could boost the availability of antidotes.  
 
8) Involving patients, carers or family members in the project 
The main pharmacists of all Belgian hospitals with an emergency department were involved in the questionnaire. 
Because of the retrospective character of the study, patients or family members were not directly involved. 
 
9) Ethics Approval 
The study protocol was approved by the Ethical Committee of the Belgian Poison Centre. 
 
10) Conflicts of interest 
The authors report no conflict of interest. 
 
  
